Prognostic relevance of molecular measurable residual disease detection in AML with mutated <i>CEBPA</i>.

Hemasphere · 2024 · PMC11326717 · PMID 39148661

Europe PMC DOI

hedged sentence

0.1200

closest p · 2.4× alpha

0.1200

boldest claim

The sentences

a nonsignificant trendp = 0.12not close (p > 0.1)

In contrast, detectable MRD in CEBPA non‐bzip AML patients showed a nonsignificant trend towards increased CIR and inferior OS ( p = 0.12 and p = 0.24; Figure 1E,F ).

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.